RIGL Rigel Pharmaceuticals

$RIGL Arvinas reported total Q3 2026 revenue of $0.5 million - and their press release states that the quarter’s revenue “consisted of sales-based royalties from the Rigel License Agreement.” Another $0.5 million likely went to Pfizer because of the 50/50 royalty split. That means Rigel probably paid around $1M in total royalties for the quarter. Assuming the combined royalty rate was around 20%...that would imply roughly $5M in Veppanu sales. We do not know the exact royalty percent owed but I think a reasonable revenue range is $4–7M depending on the actual royalty tier. Veppanu only launched on August 13 so that would be a pretty solid first seven weeks of sales!!

$RIGL is ranked #2 in healthcare balanced with a score of 84. I posted these rankings yesterday, but I think they're worth sharing again. I bought yesterday because money is made when the markets are down. I used Stock Meadow's scoring model to find what I'm buying.

$RIGL this board is so quiet…Q3 was great! Earnings beat, and strong Vep launch. Very happy here. Looking forward to ASH next month.

$RIGL • 7 trade days until earnings • 19.24% short (approx 3 million) • 198k volume/day past 2 weeks • 15 days to cover (based on past 2 weeks of volume) • First in class data just released for Gavreto • Veppanu hit market recently • guided higher already but no Vepp sales taken into that equation You do the math.. Very good time to be a Rigel Shareholder.

$RIGL not really one for short term predictions, but I think the bottom is in and we’re on our way back up. Too many good things happening for this profitable company. The future is bright!

$RIGL JMO, but Rigel’s release today 1 week prior to the meeting was to send a message. We’ve got kick butt data next week, followed by earnings the following. Check!

$RIGL So in Dec they have Ash and Breast Cancer meeting. Early Jan unaudited earnings. Santos says there majore focus is on Vep but Tav still had record numbers and Rez still growing. The question for me going forward, the growth of Vep. It sounds like the majority of there efforts on commercial is here. But no doubt they will have 300+ revenue for 2026. Will they have 300, 400, 500 for 2027? Current market cap 700 million. And those that say EPS, they are cash flow positive and funding aggressive growth. Growing cash position of 100 million. Very little debt. Probably the lowest by far. And I think it would be awful to pay taxes on EPS than spend it on future growth.

$RIGL Expected contract revenue of 35mil for the year and solid sales for veppanu sale... This was a great quarter. Q4 is set up to be massive. Buy the dip! My estimate for Q4 is: Contract: 10 mil Tavalisse: 47 mil Rezlidhia: 11 mil Gavreto: 9.5mil Veppanu: 15-20 mil Total: 92-95 mil or 31-34percent you I think we'll see 310-315 mil on total revenue for 2026

$RIGL OK...this is typical for a small cap like RIGL with a substantial short position. They want you to sell so they can cover and then they start buying themselves and go long. I listened to the call and the optimism on VEPPANU and R289 really is all over the place. Reading between the lines, R289 results will be within expectations and enough to get an early FDA approval (sometime first half of 2028). ASH will confirm this. Veppanu...well $6.6M in 6 weeks is really amazing and points to $20M in sales in q4 AT LEAST. So, growth in total revenues will continue, also when looking at royalties and milestone payments which are growing nicely as well (over $10M can be expected in q4). Rezlidhia continuing its slow growth, Tavalisse however may have come to a standstill in the US but in early stages in other parts of the world. It will continue to bring in enough to cover the additional expenses from R&D and SG&A. Overall looking great...if they bring PPS down more tomorrow, I am adding!

$RIGL I love this company. They can manipulate it however possible but, in the end, if they take it down to attractive levels again, I will buy. $6.6M in sales for a partial quarter (since mid August) of VEPPANU sales? That's freaking amazing. This is one of those companies that you can just sleep on and check back in a year and it'll have more than doubled. GLTA longs!!!

$RIGL from Friday's hc wainwright's report: "HC Wainwright has a "Buy" rating and a $85.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $2.98 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' FY2028 earnings at $5.21 EPS, FY2029 earnings at $5.96 EPS and FY2030 earnings at $7.03 EPS.

$RIGL Vep did 6.6M in the first 6 weeks. There are 18.68M shares outstanding. 6.6M per 6 weeks would be 57.2M per year or $3.06 per share and obviously Vep sales will scale up much higher.

$RIGL Added 50 more shares with change found in couch cushions. This is so cheap it’s ridiculous. 3 years from now earnings are going to be $20 a share. Let’s enjoy the ride 🚀

$RIGL What is interesting to me is that there is little discussion on this board about Alison Hannah's very clear and honest assessment on R289. It was appropriate timing as AstraZeneca dropped their Ph1/2 IRAK4 inhibitor being developed for myelodysplastic syndromes and chronic myelomonocytic leukemia. This study wass previously paused in 4/26 due to cases of liver tox IMO, it is probable that it was ultimately stopped due to liver tox issues. Why do I bring this up? I bring it up because Rigel's own 2025 ASH presentation cited that 24% of patients had ALT/AST elevation and that 9% has grade 3 or 4 ALT/AST elevations. Hannah made clear that they just determine if LR-MDS is the appropriate indication for R289 as these patients are elderly, transfusion-dependent, and have already failed multiple treatments. Raul seem to be pushing for registational studies in the face of her caution. Reminded me of when he sped up wAIHA enrollment and we all know how that ended....

$RIGL trimmed some other positions to buy another 1,000 shares. R289 and Q4 with an entire quarter of sales for veppanu is to exciting for me to miss. I’d be astounded if this wasn’t the bottom. But I’ve been wrong before! 😂

$RIGL $6.6M Veppanu sales, over 100 customers already. $350K annually per patient. This is Rigel’s first true blockbuster

$RIGL So what are the thoughts on todays earnings? I have a gut feeling its going to do better then expected.

$RIGL Any of you fellow Rigelians dumping?? I don't think so because the volume is anemic for such a day. Shorts can't buy a break!

$RIGL 119k shares traded yesterday. That just seems like stock constipation. Time will tell what weak hands will do. First time we shot to 52, many exited with little profit as they entered during Covid hype. This time, it doesn’t feel the same because we have a fourth drug Rigel touts could be there biggest yet. Once guidance has been raised, and even without Vep they needed to raise (do the math with even small growth) they are going past 295. Vep will be interesting. It will start slow, no doubt. However, it was a bit different. Due to the sale of commercial rights, it reached formularies prior to launch. There was also genetic tests launched and ready prior. So those centers that were prepared could take advantage on day one. Just interested if that makes a small impact. Sales of 5 million vs 2.5. Those are not actual numbers, just example. 7 more trading days, and we will know. What’s the next peak we will see soft hands exit? GLTA.

$RIGL data solidifies Gavreto’s position as a premier first-line option, makes Rigel’s oncology portfolio more attractive to potential partners and reinforces prescribing confidence, which will likely boost top-line revenue over time. Couple this with the upcoming Vepp sales and we are positioned well!